Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Trastuzumab Rezetecan Cycles in Early HER2-positive Breast Cancer
ChiCTR2600129981Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of trastuzumab rezetecan in breast cancer (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Total Pathological Complete Response. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600129981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129981.